Sirtris Pharmacuticals announced today that Paul Friedman, president and CEO of biotech concern, Incyte Coproration, was joined its board of directors. This addition complements other industry leaders on the board including Jeffrey Capello, SVP and CFO, PerkinElmer, Inc.,
Stephen Hoffman, Ph.D., M.D., Chairman (and former CEO) of Allos Therapeutics, Inc., Richard Pops, Chairman (and former CEO) of Alkermes, Inc. Incyte Corporation is a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases. Incyte has a market capitalization of $863 million and a enterprise value close to $1 Billion.
It is interesting to observe the stream of executives from competitors and potential partners populating the Sirtris board. The industry contacts available to this board are certainly widespread. It wouldn't be a surprise if a joint venture with a major player happens sooner than the timeframe that Sirtris management has been guiding to. The recently approved patent approval granted to the company on resveratrol like NCE compounds, certainly puts Sirtris in a stronger negotiating position for a deal to happen.
Showing posts with label sirtuins resveratrol longevity. Show all posts
Showing posts with label sirtuins resveratrol longevity. Show all posts
Tuesday, March 25, 2008
Wednesday, March 19, 2008
Sirtris Issued Important Patent on SIRT1 Activators
Sirtris Pharmacueticals reported today a significant milestone in its strategy to become the gatekeeper to the technology involved in the activation of the SRT1 enzyme in stating that "the United States Patent Office issued to Sirtris the first patent covering a broad class of compounds that activate the enzyme SIRT1." The significance of this patent, in my opinion, is related to the phrase "broad class". It has been a goal of Sirtris to effectively control the platform of compounds that activate sirtuins. This achievement can be viewed a significant step in that goal.
If the Sirtuin platform proves to be as promising for drug development in diseases of the aging as early indications seem to indicate, this patent could be remembered as the inflection pointed that started it all for Sirtris. The obvious upside of the patent is that big pharma is much more likely to partner with Sirtris than to pursue sirtuin research on its own and risk patent infringement issues.
For those interesting in learning more about sirtuins and their promise, read through the earlier blogs on this post.
If the Sirtuin platform proves to be as promising for drug development in diseases of the aging as early indications seem to indicate, this patent could be remembered as the inflection pointed that started it all for Sirtris. The obvious upside of the patent is that big pharma is much more likely to partner with Sirtris than to pursue sirtuin research on its own and risk patent infringement issues.
For those interesting in learning more about sirtuins and their promise, read through the earlier blogs on this post.
Thursday, December 20, 2007
Pharmion Just Getting Started with Sirtuins
From a recent Pharmion SEC Filing:
"The Company made significant progress in the third quarter advancing its product pipeline. Pharmion initiated several clinical studies across its portfolio, including a Phase 3 study in small cell lung cancer for Amrubicin, Phase 1 and Phase 2 studies in solid tumors and CLL for MGCD0103, opened centers and began enrolling patients in the dose escalation study for oral Azacitidine, and commenced our research program targeting sirtuin inhibitors. Research and development (R&D) expenses totaled $29.1 million for the third quarter of 2007, compared to $16.7 million for the third quarter of 2006. For the nine months ended September 30, 2007, research and development costs totaled $72.0 million, compared to $50.2 million for the nine-month period ended September 30, 2006."
It is very interesting to see that a large cap pharma is just now initiating its research into Sirtuins. Sirtris has over 140 patents in this area and with this intellectual property is attempting to position itself as the gatekeeper of Sirtuin technology. These patents could prove to be especially valuable as this field of science progresses.
"The Company made significant progress in the third quarter advancing its product pipeline. Pharmion initiated several clinical studies across its portfolio, including a Phase 3 study in small cell lung cancer for Amrubicin, Phase 1 and Phase 2 studies in solid tumors and CLL for MGCD0103, opened centers and began enrolling patients in the dose escalation study for oral Azacitidine, and commenced our research program targeting sirtuin inhibitors. Research and development (R&D) expenses totaled $29.1 million for the third quarter of 2007, compared to $16.7 million for the third quarter of 2006. For the nine months ended September 30, 2007, research and development costs totaled $72.0 million, compared to $50.2 million for the nine-month period ended September 30, 2006."
It is very interesting to see that a large cap pharma is just now initiating its research into Sirtuins. Sirtris has over 140 patents in this area and with this intellectual property is attempting to position itself as the gatekeeper of Sirtuin technology. These patents could prove to be especially valuable as this field of science progresses.
Subscribe to:
Posts (Atom)
